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Integrated Biomedical Technology Research
Resources for Proteomics and Glycomics
The National Center for Research Resources
(NCRR) proposes to foster the development of
improved technologies and methods for proteomics
and glycomics research by sponsoring integrated bio-
medical technology research resources through the
P41 mechanism. One way to confront the growing
analytical challenges of the genome era is to pursue
technology development primarily along integrated
lines of inquiry rather than single technologies. This
is particularly true in the field of proteomics. The
focus of these integrated research resources will be to
develop a range of innovative analytical tools and
methods, and apply these tools to biologically signif-
icant problems. The resources will also provide
broad access to these integrated technologies
through collaboration, service, training, and dissemi-
nation activities.
Proposed integrated research resource centers
should focus on the core technological and method-
ological problems of proteomics. Responses with
special expertise in analytical glycobiology are
encouraged, and this solicitation is open to uncon-
ventional or alternative approaches. Regardless of the
specific experimental approaches taken in pro-
teomics experiments, a common theme in this field
is the need for synergy among three principal
domains: 1) biological competencies, 2) analytical
chemistry, and 3) computational tools. These
domains should each inform the development of
tools and methods in their counterpart areas.
Accomplishing this goal in a climate of specialization
demands a fundamentally collaborative approach.
It is anticipated that these integrated centers
may be significantly larger and more complex than a
more narrowly defined research resource. These cen-
ters may be expected to draw together the expertise
of experienced investigators whose areas of special-
ization and established research focus will contribute
to the overall goals of the project. Because of the
need for integration of technologies at a fundamen-
tal level, it is considered critical that participating
investigators be in a position to work closely togeth-
er in an iterative manner. 
Development of complex integrated approaches
to proteomics problems will require a context within
which development of methods can proceed.
Investigators may wish to select a model system or
define a biological research topic that will serve as a
framework for the technological research and devel-
opment activities of the resource. Investigators will
be expected to clearly define the scope of their activi-
ties, and this definition should inform their choice
of biological context, if any.
Integrated research resources in proteomics will
eventually be expected to have a broad-based signifi-
cant impact on a variety of biological problems,
through both collaborative projects and those initiat-
ed within the resource. However, ultimately the
most important deliverables will be state-of-the-art
technology and methods for proteomics research.
Posttranslational modification is a point of
concern in the development of strategies for pro-
teomics. Because these modifications cannot be
inferred directly from gene sequence, they generally
can only be characterized directly. This raises issues
about sequence coverage and stoichiometry of mod-
ifications that are not presented by proteomics
problems focused on protein identification. In par-
ticular, the complexity and diversity of glycosylation
events significantly complicates the linkage between
genetic sequence and mature, active proteins.
Because glycosylation is mediated by a wide range
of factors, discovery-based analytical tools that can
survey the complexities of glycosylation on a sys-
temwide basis may have significant biological impact.
Besides obstacles presented by proteomics in
general, glycobiology-focused proteomics (glycomics)
requires the development of novel approaches and
tools directed at the special challenges of glycobiolo-
gy. Strategies for separation, profiling, quantitation,
and detailed characterization of carbohydrate struc-
tures are central challenges. Bioinformatics tools are
needed for data handling and reduction, correlation
of carbohydrate and protein information, recognizing
shifts in glycoprotein microheterogeneity, and model
building. Synthesis, 3-D structural analysis, and a
variety of other carbohydrate-specific analytical tools
may prove necessary to varying degrees, depending
on the global strategies adopted and thematic focus
of a center.
Ultimately, laboratories engaged in glycomics
will need the tools of mainstream proteomics as
well as these additional specialized capabilities.
Because of the breadth of challenges inherent in
developing effective tools in both proteomics and
glycomics, we encourage laboratories with special
expertise in analytical glycobiology to address those
technological problems that are inherent in and
unique to glycomics.
The deadline for letters of intent is January 1,
May 1, and September 1. Applications must be pre-
pared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398
is available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format.
Complete information on this announcement is
available at http://grants1.nih.gov/grants/guide/
pa-files/PA-02-132.html.
Contact: Douglas M. Sheeley, Division of
Biomedical Technology, NCRR, 6705 Rockledge
Drive, MSC 7965, Bethesda, MD 20892-7965 USA,
301-435-0755, fax: 301-480-3659, e-mail:
sheeleyd@ncrr.nih.gov. Reference: PA No. PA-02-132
Basic and Preclinical Research on Complementary
and Alternative Medicine
The National Center for Complementary and
Alternative Medicine (NCCAM) invites applica-
tions to help stimulate the amount and elevate the
quality of basic, mechanistic, and preclinical
research in all domains of complementary and
alternative medicine (CAM) to provide a stronger
foundation for ongoing and planned clinical stud-
ies. The NCCAM encourages the most rigorous
CAM and conventional researchers to focus on the
opportunities in CAM research, and to use the
most current and emerging technologies to
strengthen the biomedical research knowledge
bases needed to elevate clinical practice. Chemists,
physicists, psychologists, neuroscientists, endocri-
nologists, immunologists, geneticists, pharmacolo-
gists, and others in relevant fields of inquiry are
encouraged to apply. The National Cancer
Institute, the National Institute of General Medical
Sciences, and the National Institute of Mental
Health share programmatic interests in some areas
of CAM research with the NCCAM. 
To strengthen the biomedical research knowl-
edge bases needed to inform CAM clinical practice,
more basic, mechanistic, and preclinical research is
needed across the broad spectrum of biomedical sci-
ence underlying CAM practices. These practices may
be grouped in five major domains—alternative med-
ical systems, mind–body interventions, biologically
based treatments, manipulative and body-based
methods, and energy therapies—with some overlap
across categories. 
The individual systems and treatments within
each category of CAM are numerous, so the follow-
ing examples are presented to demonstrate the broad
range of research contemplated by this initiative, and
are not meant to be exclusive: 1) immunomodulatory
mechanisms underlying CAM therapeutics, such as
basic and animal model studies aimed at determining
whether and what changes are induced in immune
response pathways by CAM therapeutics, and
whether any such changes might be relevant to
resolving a disorder or preventing one; 2) neurophys-
iological, neuroendocrinological, and biochemical
pathways in massage therapy, including studies utiliz-
ing animal models, and instrumentation-based
approaches including imaging; 3) mechanistic studies
of biologically based treatments, herbs, nutritional
supplements, or natural products for enhancing cog-
nitive function in brain disorders; 4) chemical and
physical reactions during the dilution process and the
principles of biophysics associated with homeopathy;
5) mechanisms underlying the biochemical and/or
neurophysiological causes of spinal dysfunction, and
investigations of the therapeutic pathways being
impacted by manual therapies such as spinal manipu-
lation and mobilization as performed in chiropractic
or osteopathic practices; 6) studies on the rationales
for the use of complex products from a single plant
species and studies to evaluate the mechanisms of
action and to help establish the biomedical bases for
the belief in the therapeutic efficacy of using multiple
plant species simultaneously; 7) basic biological
mechanisms and processes underlying acupuncture;
8) identification and properties of bioenergies used in
treatment modalities, especially new biophysical
approaches involving instrumentation; 9) mecha-
nisms of action of saw palmetto, PC-SPES, Pygeum
africanum, and other complex botanicals on the male
reproductive tract; and of black cohosh, red clover,
and other complex botanicals on the female tract;
focusing on the cellular, molecular, endocrinological,
and metabolic changes induced in vitro, in animal
models, and in human subjects treated with these
botanicals; and 10) interactions between CAM and
conventional therapeutic modalities, including but
not limited to those of complex botanicals with phar-
maceutical drugs.
Applications must use the PHS 398 research
grant application instructions and forms (rev.
5/2001). The PHS 398 is available at http://grants.
nih.gov/grants/funding/phs398/phs398.html in an
interactive format. Applications submitted in response
to this PA will be accepted at the standard application
deadlines, which are available at http://grants.
nih.gov/grants/dates.htm. Complete information on
this PA is available online at http://grants.
nih.gov/grants/guide/pa-files/PA-02-124.html.
Contact: Neal B. West, Program Officer,
NCCAM, Two Democracy Plaza, Suite 401, 6707
Democracy Boulevard, Bethesda, MD 20892-5475
USA, 301-402-5867, fax: 301-480-3621, e-mail:
westn@mail.nih.gov; Wendy B. Smith, Program
Director, Office of Cancer Complementary and
Alternative Medicine, NCI, 6130 Executive
Boulevard, EPN, Suite 102, MSC 7302, Bethesda,
MD 20892-7302 USA, 301-435-7980, fax: 301-
480-0075, e-mail: smithwe@mail.nih.gov; Michael
E. Rogers, Director, Pharmacology, Physiology, and
Biological Chemistry Division, NIGMS, Room
2As.49c, Natcher Building, Bethesda, MD 20892-
6200 USA, 301-594-3827, fax: 301-480-2802, e-
mail: RogersM@nigms.nih.gov; or Linda Brady,
Division of Neuroscience and Basic Behavioral
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Science, NIMH, 6001 Executive Boulevard, Room
7185, Bethesda, MD 20892 USA, 301-443-5288,
fax: 301-402-4740, e-mail: lb@helix.nih.gov.
Reference: PA No. PA-02-124
Research on Ethical Issues in Human Studies
NIH invites research grant applications to investigate
ethical issues in research using human subjects. The
Code of Federal Regulations (45 CFR, Part 46) pro-
vides a regulatory framework that all NIH-supported
researchers must follow. However, recent develop-
ments in biomedical and behavioral research—
including the rapid growth of new interventions and
technologies (e.g., stem cells, genetics research),
increasing involvement of foreign populations in clin-
ical research, and concerns about financial conflicts of
interest among researchers—challenge investigators’
abilities to interpret and apply the regulations. Other
situations (e.g., research with vulnerable populations,
the use of data banks or archives, research on stigma-
tizing diseases or conditions) may present difficulties
for identifying strategies, procedures, and/or tech-
niques that will enhance and ensure the ethical
involvement of human participants in research. 
The purpose of this PA is to support empirical
research addressing the ethical challenges of involv-
ing human participants in research in order to
inform and optimize protections for human partici-
pation in research. Examples of the types of topics
that would be appropriate for applications submitted
under this announcement include, but are not limit-
ed to, the following:
Minimizing Risks in Human Research
1) Assess how features of the research and
research setting affect evaluations of risks versus
potential benefits of different types of research for
investigators, institutional review board (IRB) mem-
bers, and potential participants, groups, and com-
munities. Examples of features of the research or
research setting may include characteristics of the
participants (e.g., age, health status and stage of dis-
ease, ethnic/cultural background, cognitive capacity,
social status, gender, incarceration), aspects of the
condition/disease (e.g., prevalence, severity,
chronicity, degree of disability), and the nation or
culture in which the study will take place.
2) Identify potential social, psychological,
and/or economic harms (e.g., stigma, discrimina-
tion, personal distress, loss of insurance coverage,
loss of employment) that may be associated with
recruitment, participation, or self-determined or
study-determined withdrawal from research.
Evaluate strategies or procedures for minimizing
these harms in regard to individuals’, groups’, com-
munities’, and populations’ willingness to participate
in different types of research.
3) Assess the conditions and assumptions under
which IRB evaluation of risk versus potential bene-
fits is similar to or different from the evaluation of
risks versus potential benefits by individuals, groups,
communities, and populations.
4) Assess the impact of obtaining a certificate of
confidentiality on perceptions of IRB members
and/or participants in terms of evaluation of risks,
understanding of the research, and/or understanding
of the rights to privacy.
5) Identify and evaluate strategies for protect-
ing and minimizing disclosure of private informa-
tion when identifiable data are collected via the
Internet, preserved for secondary analysis (e.g., in a
tissue or gene bank, data archive, warehouse),
and/or collected about third parties in research (e.g.,
network studies).
Issues in Informed Consent
1) Determine how features of the informed con-
sent process affect participants’ comprehension
and/or willingness to participate in research.
Examples of these features include a) variations in
the style of presentation (e.g., oral, written, graphic,
video); b) readability, complexity, and/or format of
the consent document; c) characteristics of the partic-
ipants (e.g., language preference, age, health status,
education, cultural/ethnic background, personal
motivations, cognitive capacity); and d) contextual
features or circumstances in which informed consent
takes place (e.g., characteristics of the research staff,
location such as research hospital versus private office
versus home, presence/involvement of family mem-
bers, presence/involvement of patient advocates). 
2) Evaluate different methods and identify best-
practice strategies for consulting with communities in
the United States and/or other countries regarding
comprehension, willingness to participate, and/or
willingness to continue with research at the individ-
ual, group, community, and/or population level.
3) Assess how recontacting participants to
obtain informed consent for additional uses of their
data affects participant comprehension, willingness
to participate, and sense of coercion.
4) Identify and evaluate strategies, procedures,
and/or techniques for improving comprehension of
research by individuals, groups, communities,
and/or populations at the time of initial consent,
during, and/or after completion of the study. Also,
determine how these strategies may differ depending
on age, health status, ethnic/cultural background,
cognitive capacity, social status, and/or gender of the
target audience.
5) Assess how participants’ willingness to partic-
ipate versus sense of coercion, may be affected by use
of different types of incentives, remuneration, and/or
provision of medical care; different features of the
research setting (e.g., personal physician as recruiter
and/or researcher, private funding versus federal
funding); and characteristics of the participants (e.g.,
health status, age, ethnic/cultural background, edu-
cation, gender).
6) Assess the impact of communicating or not
communicating individual test results, study
progress, and/or study results on participants’ will-
ingness to continue with the protocol and/or partici-
pate in research again.
Oversight of Research and Research Data
1) Identify and evaluate strategies to improve
the oversight of human participants protection by
IRBs, data and safety monitoring boards (DSMB),
conflict of interest (COI) committees, etc. Examples
may include a) develop and evaluate best-practice
outcome measures for decision making about the
acceptability of research protocols; b) assess the con-
sistency of protocol review decisions within DSMBs,
IRBs, or COI committees; c) assess the impact of
conflicts of interest among members of oversight
committees on decision making about the accept-
ability of research protocols, interpretations of
adverse events, and/or perceptions of “independence
of review” by the research community; and d) assess
the impact of disclosing varying degrees of financial
conflicts of interest involving the principal investiga-
tor, members of oversight committees, sponsor,
institution, etc. on research participant willingness to
participate and/or continue with research, and/or
participant understanding of the research.
2) Compare and evaluate different methods and
strategies for identifying, reporting, and handling
adverse events based on the perspectives of individ-
ual participants, institutions, DSMBs, and/or IRBs.
This PA will use the NIH R01 award mecha-
nism and Just in Time concepts. It will also use the
modular as well as the nonmodular budgeting for-
mats (see http://grants.nih.gov/grants/funding/
modular/modular.htm). Specifically, if you are sub-
mitting an application with direct costs in each year
of $250,000 or less, use the modular format.
Otherwise follow the instructions for nonmodular
research grant applications. 
Applications must be prepared using the PHS
398 research grant application instructions and
forms (rev. 5/2001). The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/phs398.
html in an interactive format. Complete information
on this PA is available at http://grants1.nih.gov/
grants/guide/pa-files/PA-02-103.html. To assist in
identifying which NIH institute/office most closely
matches your research topic, the following website
provides additional information about institute- and
office-specific research interests that will be support-
ed by this PA: http://grants.nih.gov/grants/
funding/ethics_contacts.htm.
Contact: Della M. Hann, Office of Extramural
Research, NIH, Building 1, Room 152, Bethesda,
MD 20892 USA, 301-402-2725, fax: 301-402-
3469, e-mail: hannd@od.nih.gov. Reference: PA
No. PA-02-103
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